After H.C. Wainwright and Guggenheim gave Krystal Biotech Inc (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Krystal Biotech Inc today. The company’s shares opened today at $31.65.
Prasad observed:
“We continue to view its anticipated clinical update of the GEM trial with KB103 in DEB as a significant near-term catalyst for shares (expected by the end of June).”
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 19.1% and a 55.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $44.38, a 40.2% upside from current levels. In a report issued on May 30, Guggenheim also initiated coverage with a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.95 and a one-year low of $13.60. Currently, Krystal Biotech Inc has an average volume of 101.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
